Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung

J Thorac Oncol. 2017 Sep;12(9):e135-e136. doi: 10.1016/j.jtho.2017.04.029. Epub 2017 May 10.

Authors

Zhigang Yuan¹, Allison Fromm¹, Kamran A Ahmed¹, George D Grass¹, George Q Yang¹, Daniel E Oliver¹, Thomas J Dilling¹, Scott J Antonia², Bradford A Perez³

Affiliations

¹ Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
² Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
³ Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: bradford.perez@moffitt.org.

PMID: 28502722
DOI: 10.1016/j.jtho.2017.04.029

No abstract available

Publication types

Case Reports

MeSH terms

Carcinoma, Squamous Cell / pathology
Carcinoma, Squamous Cell / radiotherapy*
Humans
Lung Neoplasms / pathology
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Neoplasm Metastasis
Nivolumab / pharmacology
Nivolumab / therapeutic use*

Substances

Nivolumab